Multiple Sclerosis

Study shows that MRI imaging can identify cortical lesions and the central vein sign that are informative in diagnosing multiple sclerosis.

Vidofludimus calcium is a potential first-in-class nuclear receptor related 1 (Nurr1) activator and a selective dihydroorotate dehydrogenase (DHODH) inhibitor.

It is believed that reasons for these racial disparities may include socioeconomic factors, but the true causes are not fully understood. Some researchers believe that immunologic differences may also play a role.

The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.

Progressive multifocal leukoencephalopathy (PML) is caused by John Cunningham virus (JCV). A recently published study suggests that the number of cases of PML related to Tysabri (natalizumab) have been decreasing perhaps as a result of increased monitoring.

Swoop, a New York-based company, has launched an algorithm that may help people with multiple sclerosis take medications as prescribed.

Researchers in Serbia identified link between autonomic symptom burden and quality of life.

Optical coherence tomography was found to be comparable with MRI in detecting changes to the retina in patients with multiples sclerosis and is non-invasive, inexpensive, fast, and easy to perform.

In a study recently published in Neurology, researchers investigated the relationship between early treatment and the risk for long-term disability in patients with clinically isolated syndrome.

Ibudilast is a small molecule being developed by biopharmaceutical company MediciNova for the potential treatment of MS. The company, based in La Jolla, California, is currently calling the oral formulation MN-166.

Researchers have been working on sorting out the causal direction of multiple sclerosis (MS) and depression. These findings suggest that depression can be a consequences of MS-related disability not the other way around.

Mutations in one locus were associated with a decrease in the median time until needing a walking aid of between 3.3 and 3.7 years.

The researchers conclude that it is “reasonable option” for older patients with stable multiple sclerosis (MS) to stop taking disease-modifying therapy because the risk of relapse from doing so is small.

Patients with multiple sclerosis (MS) with a plant-rich diet had less symptom burden compared with patients with MS who had an elevated intake of red meat and processed meat.

Improvements have been indicated by a large decrease in the relapse rate during their third trimester of pregnancy.

Merck and Sanofi’s Bruton tyrosine kinase inhibitors were dealt setbacks when the FDA put partial clinical holds on their development because of liver toxicity issues.

Chronic prescription opioid use is common among a sizable minority of veterans with MS, according to a recent study.

Plans call for 12 sites and two advisory boards.

The VIDAMS trial compared daily of 5,000 international units (IUs) to 600 IUs.

The FDA decision is based on increased liver enzyme levels seen in two participants during the phase 3 studies.

Neurologists may feel ill-equipped to manage or identify sexual problems of multiple sclerosis patients, wrote the authors, but it's important they ask patients about sexual function and satisfaction.

But transcutaneous electrical nerve stimulation (TENS) edged out interferential current therapy (IFT) on several measures.

The Multiple Sclerosis International Federation has applied to have Rituxan, Mavenclad and Copaxone added to the World Health Organization’s list of essential medications.

The newly approved treatment for relapsing multiple sclerosis is priced at $59,000 per year. The Institute for Clinical and Economic Review said it should be priced at between $16,000 and $34,900 to meet commonly accepted thresholds for cost effectiveness.